– USA, MA – Aviceda Therapeutics, a biotech company focused on developing next-generation immunomodulators, today announced the appointment of Patrick Johnson to its Board of Directors.
“We are thrilled to welcome Patrick to Aviceda’s board of directors as we advance our pipeline through key milestones in 2023 and beyond. Patrick will bring significant industry expertise, and his strategic counsel will be invaluable to Aviceda as we continue to advance our technology platform in late-stage clinical development for patients with GA due to age-related macular degeneration and broader therapeutic applications,” said CEO and co-founder, Dr. Mohamed Genead.
About Patrick Johnson
Patrick Johnson is an accomplished business leader and entrepreneur with a proven track record of enabling pharmaceutical and biotechnology companies to maximize their brands’ value and realize their innovations’ potential.
Patrick is a strategic pharmaceutical executive with two decades of broad cross-functional expertise in all aspects of corporate operations, including in-depth experience with global M&A, business development, strategic transactions, fundraising, clinical operations, scientific research, and corporate finance. Previously, he gained exceptional sell-side and buy-side transactional experience as head of business development for eye care and drug delivery at Allergan. Patrick’s deal experience ranges from some of the largest transactions in the pharmaceutical industry to small partnerships, having raised multiple rounds of venture financing for numerous start-up companies. He is currently leading operations on global Phase 3 clinical studies as President of Sydnexis Inc. Co-author of a global patent portfolio and author/co-author of numerous peer-reviewed journal articles, Patrick also has specific subject matter expertise with a Ph.D. in retinal development and post-doctoral research in retinal degeneration.
“It is a privilege to join Aviceda’s board as the organization advances towards delivering new treatment options for people living with retinal diseases, many of whom have been significantly underserved for decades,” said Dr. Johnson. “I look forward to working alongside this dynamic team and advancing a diverse pipeline through development and into commercialization.”
About Aviceda Therapeutics
Aviceda is a private clinical-stage biotechnology company located in Cambridge, MA, with a proprietary HALOS nanotechnology platform and an IND-cleared ophthalmic lead product for geographic atrophy secondary to age-related macular degeneration.
Aviceda has a broad pipeline of products in development in ophthalmology and multiple other therapeutic areas, including neurology, oncology, fibrosis, and immunology.
For more information: https://www.avicedarx.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
